• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alector Inc. (Amendment)

    2/9/24 4:48:56 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email
    SC 13G/A 1 d728701dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO 13d-2 (b)

    (Amendment No. 4)

     

     

    Alector, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    014442107

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Partners VI, L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    498,468 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    498,468 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    498,468 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.5% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such shares are held of record by PVP VI (as defined in Item 2(a) of the Original Schedule 13G). PVM VI (as defined in Item 2(a) of the Original Schedule 13G), the general partner of PVP VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding, as reported in the Issuer’s prospectus (File No. 333-270126) filed with the United States Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b)(5) on January 17, 2024 (the “Prospectus”) and assuming the underwriter does not exercise its option to purchase additional shares of Common Stock in full in connection with the offering described in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Partners Founders’ Fund VI, L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    599,251 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    599,251 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    599,251 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.6% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such shares are held of record by PVPFF VI (as defined in Item 2(a) of the Original Schedule 13G). PVM VI, the general partner of PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Partners VI (AIV), L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    7,831,004 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    7,831,004 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,831,004 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    8.2% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such shares are held of record by PVP VI (AIV) (as defined in Item 2(a) of the Original Schedule 13G). PVM VI, the general partner of PVP VI (AIV), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Partners VI (AIV-B), L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    1,925,094 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    1,925,094 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,925,094 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    2.0% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such shares are held of record by PVP VI (AIV-B) (as defined in Item 2(a) of the Original Schedule 13G). PVM VI, the general partner of PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Management Co VI, L.L.C.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    10,853,817 (1)

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    10,853,817 (1)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,853,817 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.4% (2)

    12   

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    498,468 of such shares are held of record by PVP VI, 599,251 of such shares are held of record by PVPFF VI, 7,831,004 of such shares are held of record by PVP VI (AIV) and 1,925,094 of such shares are held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    David Barrett

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    10,853,817 (1)

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    10,853,817 (1)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,853,817 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.4% (2)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    498,468 of such shares are held of record by PVP VI, 599,251 of such shares are held of record by PVPFF VI, 7,831,004 of such shares are held of record by PVP VI (AIV) and 1,925,094 of such shares are held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Brian Chee

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    30,749 (1)

        6   

    SHARED VOTING POWER

     

    10,853,817 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    30,749 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    10,853,817 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,884,566 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.5% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by Brian Chee directly.

    (2)

    498,468 of such shares are held of record by PVP VI, 599,251 of such shares are held of record by PVPFF VI, 7,831,004 of such shares are held of record by PVP VI (AIV) and 1,925,094 of such shares are held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Jonathan A. Flint

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    58,686 (1)

        6   

    SHARED VOTING POWER

     

    10,853,817 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    58,686 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    10,853,817 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,912,503 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.5% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by Jonathan A. Flint directly.

    (2)

    498,468 of such shares are held of record by PVP VI, 599,251 of such shares are held of record by PVPFF VI, 7,831,004 of such shares are held of record by PVP VI (AIV) and 1,925,094 of such shares are held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Terrance G. McGuire

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    121,917 (1)

        6   

    SHARED VOTING POWER

     

    10,853,817 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    121,917 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    10,853,817 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,975,734 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.5% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    28,746 of such shares are held of record directly by Terrance G. McGuire and 93,171 of such shares consist of Common Stock subject to stock option awards that have been granted to Terrance G. McGuire in his capacity as a director of the Issuer and that are exercisable as of or within 60 days of the filing of this Amendment No. 4 (as defined in the Introductory Note below). Excludes 3,090 shares of Common Stock subject to option awards that have been granted to Terrance G. McGuire in his capacity as a director of the Issuer and that are exercisable as of now or within 60 days of February 14, 2024.

    (2)

    498,468 of such shares are held of record by PVP VI, 599,251 of such shares are held of record by PVPFF VI, 7,831,004 of such shares are held of record by PVP VI (AIV) and 1,925,094 of such shares are held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based upon 95,099,118 shares of the Issuer’s Common Stock, calculated as follows: (i) 93,171 shares of the Issuer’s Common Stock subject to stock option awards or that represent restricted stock units that have been granted to Mr. McGuire in his capacity as director of the Issuer and that are exercisable as of or within 60 days of the filing of this Amendment No. 4 plus (ii) 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Amir Nashat

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    13,133 (1)

        6   

    SHARED VOTING POWER

     

    10,853,817 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    13,133 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    10,853,817 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,866,950 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.4% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by Amir Nashat directly.

    (2)

    498,468 of such shares are held of record by PVP VI, 599,251 of such shares are held of record by PVPFF VI, 7,831,004 of such shares are held of record by PVP VI (AIV) and 1,925,094 of such shares are held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

     

     1   

    NAME OF REPORTING PERSONS

     

    Bryce Youngren

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    34,399 (1)

        6   

    SHARED VOTING POWER

     

    10,853,817 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    34,399 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    10,853,817 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,888,216 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.5% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by Bryce Youngren directly.

    (2)

    498,468 of such shares are held of record by PVP VI, 599,251 of such shares are held of record by PVPFF VI, 7,831,004 of such shares are held of record by PVP VI (AIV) and 1,925,094 of such shares are held of record by PVP VI (AIV-B). PVM VI, the general partner of each of PVP VI, PVPFF VI, PVP VI (AIV) and PVP VI (AIV-B), may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, a member of the Issuer’s board of directors, Amir Nashat, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based upon 95,005,947 shares of the Issuer’s Common Stock outstanding as of January 17, 2024, as set forth in the Prospectus.


    CUSIP #014442107

    SCHEDULE 13G

    Introductory Note: This Amendment No. 4 (this “Amendment No. 4”) amends and supplements the Schedule 13G initially filed with the Commission on February 12, 2020, as amended by Amendment No. 1 filed with the Commission on February 12, 2021, Amendment No. 2 filed with the Commission on February 11, 2022 and Amendment No. 3 filed with the Commission on February 7, 2023 (collectively, the “Original Schedule 13G”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 4 have the meanings ascribed to them in the Original Schedule 13G.

    ITEM 2(B). ADDRESS OF PRINCIPAL OFFICE

    The address for each of the Reporting Persons except for Chee is:

    c/o Polaris Partners

    One Marina Park Drive, 8th Floor

    Boston, MA 02210

    The address for Chee is:

    c/o Polaris Partners

    1 Letterman Drive

    Building C, Suite 3600

    San Francisco, CA 94129

    ITEM 4. OWNERSHIP 

    Except as otherwise indicated on the cover pages for the Reporting Persons, the following information with respect to the ownership of the common stock of the Issuer by the Reporting Persons filing this Statement is provided as of December 31, 2023:

    (a) Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person and the corresponding footnotes.*

    (b) Percent of Class:

    See Row 11 of cover page for each Reporting Person and the corresponding footnotes.*

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person and the corresponding footnotes.*

    (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his, her or its pecuniary interest therein.


    CUSIP #014442107

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 9, 2024

     

    POLARIS VENTURE PARTNERS VI, L.P.
    By: Polaris Venture Management Co. VI, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS VENTURE PARTNERS VI (AIV), L.P.
    By:   Polaris Venture Management Co. VI, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS VENTURE PARTNERS VI (AIV-B), L.P.
    By:   Polaris Venture Management Co. VI, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS VENTURE PARTNERS FOUNDERS’ FUND VI, L.P.
    By:   Polaris Venture Management Co. VI, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS VENTURE MANAGEMENT CO. VI, L.L.C.
    By:   *
      Authorized Signatory
    JONATHAN A. FLINT
    By:   *
      Jonathan A. Flint


    TERRANCE G. MCGUIRE
    By:   *
      Terrance G. McGuire
    BRYCE YOUNGREN
    By:   *
      Bryce Youngren
    DAVID BARRETT
    By:   *
      David Barrett
    BRIAN CHEE
    By:   *
      Brian Chee
    AMIR NASHAT
    By:   *
      Amir Nashat
    *By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
      Attorney-in-Fact

    [*This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $ALEC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    12/4/2024$9.00 → $1.00Neutral → Underperform
    BofA Securities
    11/29/2024$35.00 → $7.00Buy
    H.C. Wainwright
    11/26/2024$10.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    12/14/2023$8.00 → $15.00Hold → Buy
    Stifel
    12/12/2023$12.00Buy
    Deutsche Bank
    9/25/2023$4.00Sell
    Goldman
    More analyst ratings

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alector Reports First Quarter 2025 Financial Results and Provides Business Update

      Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, toda

      5/8/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Participate in Upcoming Healthcare Conferences

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York) Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat A webcast of each conference presentation will be available on the "Events & Presentations" page w

      5/6/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ALEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alector downgraded by Mizuho with a new price target

      Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $2.50 from $9.00 previously

      12/17/24 7:23:27 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by Stifel with a new price target

      Stifel downgraded Alector from Buy to Hold and set a new price target of $4.00

      12/16/24 6:41:43 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by BofA Securities with a new price target

      BofA Securities downgraded Alector from Neutral to Underperform and set a new price target of $1.00 from $9.00 previously

      12/4/24 7:19:54 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alector Inc.

      SC 13G - Alector, Inc. (0001653087) (Subject)

      12/6/24 5:30:28 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/12/24 7:21:57 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/7/24 12:41:31 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Alector Inc.

      10-Q - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:15:17 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:10:08 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Alector Inc.

      DEFA14A - Alector, Inc. (0001653087) (Filer)

      4/24/25 4:02:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scheller Richard H was granted 15,833 shares, increasing direct ownership by 31% to 66,666 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      5/2/25 6:00:09 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Grasso Marc sold $26,547 worth of shares (18,091 units at $1.47), decreasing direct ownership by 5% to 312,560 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:13 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Rosenthal Arnon sold $59,176 worth of shares (40,330 units at $1.47), decreasing direct ownership by 2% to 2,466,744 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:18 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Alector Reports First Quarter 2024 Financial Results and Provides Business Update

      Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

      5/8/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

      3/29/22 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. 

      2/7/22 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Financials

    Live finance-specific insights

    See more
    • Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

      2/26/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and follo

      2/19/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

      Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease anticipated in mid-2025, with approximately 75% target recruitment achieved $457.2 million in cash, cash equivalents and investments as of September 30, 2024, expected to fund operations through 2026 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLO

      1/13/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care